Federal Testosterone Replacement Lawsuits Consolidated

Oklahoma men and their loved ones who have filed lawsuits because they experienced heart attacks, strokes or other adverse effects after receiving testosterone treatments will likely find their cases transferred to the newly created federal MDL in Chicago.

If you or your loved one has received any kind of testosterone replacement therapy and has experienced a heart attack, stroke, deep vein thrombosis, infertility or death, you may be able to receive compensation through legal action for your medical bills, lost income and other suffering and losses.

The Judicial Panel for Multidistrict Litigation earlier this month combined all federal cases against the manufacturers of several testosterone replacement treatments into a single MDL (MDL-2545) in the Northern District of Illinois before U.S. District Judge Matthew F Kennelly.

According to the panel’s monthly statistical report, on June 16 the MDL has 96 pending cases. That number is expected to quickly jump to several hundred or more lawsuits.

The defendant in many of the lawsuits is AbbieVie, and its former parent company Abbott Laboratories. AbbieVie manufactures AndroGel, the most widely used testosterone therapy. The daily gel was approved by the FDA in 2000.

Other products and manufacturers targeted in lawsuits included in the MDL are:

  • AndroDerm, a daily patch manufactured by Actavis, formerly Watson Pharmaceuticals.
  • Axiron, a topical solution manufactured by Eli Lilly.
  • Bio-T Gel, a daily gel manufactured by GlaxoSmithKline.
  • Delatestryl, an injection manufactured by Savient Pharmaceuticals.
  • Depo-Testosterone, an injection manufactured by Pfizer. Depo-Testosterone has been used for more than 30 years, and the FDA approved a generic version last year.
  • Foresta, a spray gel manufactured by Endo Pharmaceuticals.
  • Striant, a slow-release tablet owned by Auxilium Pharmaceuticals and developed by Columbia Laboratories.
  • Testim, a gel manufactured by Auxilium.
  • Testopel, an under-the-skin implant manufactured by Slate Pharmaceuticals.

In the order creating the testosterone MDL, the Judicial Panel acknowledged the difficulties that may be involved in combining so many different products and manufacturers. However, the panel said it decided on the industry-wide MDL because:

  • “Factual questions regarding general causation and the background science” are the same for all of the products.
  • Many plaintiffs have used more than one of the prescription testosterone therapies.

The various lawsuits accuse manufacturers of:

  • Failing to adequately research the risks that testosterone treatments may cause, especially for men who already have heart disease and other health problems.
  • Failing to warn health officials and patients of those risks.
  • Being overaggressive in how they have marketed their products, luring men to seek testosterone therapies to counter the effects of growing older, such as a lower sex drive and being tired, even if they men have not been diagnosed with “Low T.”

Pfizer, the manufacturer of the injection therapy, Depo-Testosterone, argued that its cases should not be lumped in with the other defendants. For one thing, Pfizer contended, it has not conducted anaggressive marketing campaign for its product.

An initial status conference is set for July 10.

For more information about testosterone replacement treatments and the legal rights of patients who have received them, see “Testosterone Replacement Therapies” on this website.

If you or a loved one has received one or more testosterone treatments or therapies and has experienced heart attack, stroke, deep vein thrombosis, infertility or death, get in touch with us for a free consultation about your legal rights.

Contact Hasbrook & Hasbrook by telephone (866-416-4737), email (cth@hasbrooklaw.com) or use our website contact form: Contact Us.